All In Biotech

Drug Trial Radar · NCT04643067

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Jun 3, 2021

Primary completion

Jun 29, 2023

Study completion Jun 29, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical trial is titled "A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients with Systemic Lupus Erythematosus". This study was designed to address the following key questions: * Phase 1b: Assess safety and PK of KPG-818 in SLE patients over 14 days. * Phase 2a: Assess safety, efficacy, PD biomarkers, and PK of KPG-818 in SLE patients over 12 weeks. The study design comprises eight Cohorts, which are outlined below: * Phase 1b dose levels: Cohort A (0.15 mg/day), B (0.6 mg/day), C (2 mg/day), and D (5 mg/day). * Phase 2a dose levels: Cohort E (0.15 mg/day), F (0.6 mg/day), G (2 mg/day) and H (placebo).

Conditions

  • SLE; Drug

Interventions

  • KPG-818 low dose in phase 1bDrug

    Patients received 0.15 mg/day of KPG-818 once daily for up to 14 days.

  • KPG-818 mid dose in phase 1bDrug

    Patients received 0.6 mg/day of KPG-818 once daily for up to 14 days.

  • KPG-818 high dose in phase 1bDrug

    Patients received 2.0 mg/day of KPG-818 once daily for up to 14 days.

  • KPG-818 ultra-high dose in phase 1bDrug

    Patients received 5.0 mg/day of KPG-818 once daily for up to 14 days.

  • KPG-818 low dose in phase 2aDrug

    Patients received 0.15 mg/day of KPG-818 once daily for up to 84 days.

  • KPG-818 mid dose in phase 2aDrug

    Patients received 0.6 mg/day of KPG-818 once daily for up to 84 days.

  • KPG-818 high dose in phase 2aDrug

    Patients received 2.0 mg/day of KPG-818 once daily for up to 84 days.

  • KPG-818 Placebo in phase 2aDrug

    Patients received KPG-818 Placebo once daily for up to 84 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety / Tolerability (Assessed by Adverse Events)Time frame: 4 weeks for phase 1b and 16 weeks for phase 2a
  2. Phase 1b - PK Assessment: AUC0-last of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  3. Phase 1b - PK Assessment: AUC0-∞ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  4. Phase 1b - PK Assessment: AUCτ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  5. Phase 1b - PK Assessment: Css_max of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  6. Phase 1b - PK Assessment: Css_min of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  7. Phase 1b - PK Assessment: Tmax of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  8. Phase 1b - PK Assessment: t1/2 of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  9. Phase 1b - PK Assessment: CL/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  10. Phase 1b - PK Assessment: Vz/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 7, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  11. Phase 2a - PK Assessment: AUC0-last of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  12. Phase 2a - PK Assessment: AUC0-∞ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  13. Phase 2a - PK Assessment: AUCτ of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  14. Phase 2a - PK Assessment: Css_max of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  15. Phase 2a - PK Assessment: Css_min of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  16. Phase 2a - PK Assessment: Tmax of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  17. Phase 2a - PK Assessment: t1/2 of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  18. Phase 2a - PK Assessment: CL/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.
  19. Phase 2a - PK Assessment: Vz/F,ss of KPG-818 & KPG-818HTime frame: The PK blood samples were collected at 30 minutes predose on Day 14, and at 1, 2, 6, 10, and 24 hours postdose on the same day.

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Anniston Medical Clinic

    Anniston, Alabama

  • University of Alabama - Birmingham

    Birmingham, Alabama

  • Clinical Research of West Florida, Inc.

    Clearwater, Florida

  • Hope Clinical Trials, Inc.

    Coral Gables, Florida

  • JY Research Institute Inc

    Cutler Bay, Florida

  • OSIS Clinical Research

    Hollywood, Florida

  • SouthCoast Research Center Inc

    Miami, Florida

  • D & H National Research Centers

    Miami, Florida

  • Charisma Medical and Research Center

    Miami Lakes, Florida

  • San Marcus Research Clinic

    Miami Lakes, Florida

  • Omega Research MetroWest LLC

    Orlando, Florida

  • Clinical Research of West Florida

    Tampa, Florida

  • Oracle Clinical Research

    College Park, Georgia

  • STAT Research

    Vandalia, Ohio

  • Shelby Research LLC

    Memphis, Tennessee

  • Accurate Clinical Management

    Houston, Texas

  • Accurate Clinical Research LLC

    Houston, Texas

  • Sun Research Institute

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.